| Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma T Best, D Li, AD Skol, T Kirchhoff, SA Jackson, Y Yasui, S Bhatia, ... Nature medicine 17 (8), 941-943, 2011 | 194 | 2011 |
| A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus W Cozen, MN Timofeeva, D Li, A Diepstra, D Hazelett, ... Nature communications 5 (1), 3856, 2014 | 108 | 2014 |
| A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21. 32 W Cozen, D Li, T Best, DJ Van Den Berg, PA Gourraud, VK Cortessis, ... Blood, The Journal of the American Society of Hematology 119 (2), 469-475, 2012 | 104 | 2012 |
| Long-term persistence of spike protein antibody and predictive modeling of antibody dynamics after infection with severe acute respiratory syndrome coronavirus 2 L Grandjean, A Saso, A Torres Ortiz, T Lam, J Hatcher, R Thistlethwayte, ... Clinical Infectious Diseases 74 (7), 1220-1229, 2022 | 94* | 2022 |
| A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology EA Hungate, SR Vora, ER Gamazon, T Moriyama, T Best, I Hulur, Y Lee, ... Nature communications 7 (1), 10635, 2016 | 55 | 2016 |
| Evolution of viral variants in remdesivir‐treated and untreated SARS‐CoV‐2‐infected pediatrics patients FAT Boshier, J Pang, J Penner, M Parker, N Alders, A Bamford, ... Journal of medical virology 94 (1), 161-172, 2022 | 18 | 2022 |
| Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer CL Doci, TP Mankame, A Langerman, KR Ostler, R Kanteti, T Best, K Onel, ... International journal of gynecological pathology 31 (1), 15-24, 2012 | 18 | 2012 |
| Using whole genome sequences to investigate adenovirus outbreaks in a hematopoietic stem cell transplant unit CE Myers, CJ Houldcroft, S Roy, BK Margetts, T Best, C Venturini, ... Frontiers in Microbiology 12, 667790, 2021 | 11 | 2021 |
| Remdesivir induced viral RNA and subgenomic RNA suppression, and evolution of viral variants in SARS-CoV-2 infected patients FAT Boshier, J Pang, J Penner, J Hughes, M Parker, J Shepherd, ... MedRxiv, 2020.11. 18.20230599, 2020 | 10 | 2020 |
| Capitol Records, Inc. V. Naxos OF America, Inc.: the persistence of copyright on that old time Rock N'Roll TP Best Berkeley Tech. LJ 21, 335, 2006 | 8 | 2006 |
| Humoral response dynamics following infection with SARS-CoV-2. MedRxiv. 2020 L Grandjean, A Saso, A Torres, T Lam, J Hatcher, R Thistlethwayte, ... URL: https://www. medrxiv. org/content/10.1101/2020.07 16, v2, 0 | 8 | |
| Real‐World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL). C Jacobson, MT Hemmer, Z Hu, M Frank, L Popplewell, N Ahmed, Y Lin, ... Hematological Oncology 41, 2023 | 6 | 2023 |
| Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients AY Kreins, E Roux, J Pang, I Cheng, O Charles, S Roy, R Mohammed, ... Clinical Immunology 259, 109901, 2024 | 5 | 2024 |
| S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA C Jacobson, MT Hemmer, ZH Hu, M Frank, L Popplewell, N Ahmed, Y Lin, ... HemaSphere 7, e31464ce, 2023 | 2 | 2023 |
| Matching‐adjusted indirect comparison of axicabtagene ciloleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatments. MD Ray, S Kanters, S Beygi, T Best, J Wulff, EH Limbrick‐Oldfield, ... Hematological Oncology 41, 2023 | 2 | 2023 |
| Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed/refractory follicular lymphoma MD Ray, S Kanters, S Beygi, T Best, J Wulff, E Limbrick-Oldfield, AR Patel, ... Transplantation and Cellular Therapy, 2024 | 1 | 2024 |
| Persistent low-level variants in a subset of viral genes are highly predictive of poor outcome in immunocompromised patients with cytomegalovirus infection C Venturini, JM Colston, O Charles, A Lankina, T Best, C Atkinson, ... The Journal of Infectious Diseases, jiae001, 2024 | 1 | 2024 |
| Evaluating metagenomics and targeted approaches for diagnosis and surveillance of viruses S Buddle, L Forrest, N Akinsuyi, LM Martin Bernal, T Brooks, C Venturini, ... Genome Medicine 16 (1), 111, 2024 | | 2024 |
| Matching-Adjusted Indirect Comparison of Axicabtagene Ciloleucel vs Odronextamab for the Treatment of Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) After 2 Prior Lines … FL Locke, E Popoff, SW Wade, E Limbrick-Oldfield, S Kanters, M Palivela, ... Clinical Lymphoma, Myeloma and Leukemia 24, S217, 2024 | | 2024 |
| ABCL-411 Matching-Adjusted Indirect Comparison of Axicabtagene Ciloleucel vs Odronextamab for the Treatment of Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) After 2 … F Locke, E Popoff, SW Wade, E Limbrick-Oldfield, S Kanters, M Palivela, ... Clinical Lymphoma Myeloma and Leukemia 24, S478, 2024 | | 2024 |
